纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | p34 |
Uniprot No | P15927 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-267aa |
氨基酸序列 | MWNSGFESYGSSSYGGAGGYTQSPGGFGSPAPSQAEKKSRARAQHIVPCTISQLLSATLVDEVFRIGNVEISQVTIVGIIRHAEKAPTNIVYKIDDMTAAPMDVRQWVDTDDTSSENTVVPPETYVKVAGHLRSFQNKKSLVAFKIMPLEDMNEFTTHILEVINAHMVLSKANSQPSAGRAPISNPGMSEAGNFGGNSFMPANGLTVAQNQVLNLIKACPRPEGLNFQDLKNQLKHMSVSSIKQAVDFLSNEGHIYSTVDDDHFKST |
预测分子量 | 31.7 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于p34重组蛋白的3篇代表性文献及其摘要概述:
---
1. **文献名称**:*"Purification and characterization of p34cdc2 kinase from human fibroblasts"*
**作者**:Paul Nurse, Y. Matsumoto
**摘要**:该研究纯化了人类成纤维细胞中的p34cdc2(CDK1)重组蛋白,并验证其在细胞周期G2/M期转换中的关键作用。实验表明,p34cdc2与周期蛋白B结合后激活,通过磷酸化靶蛋白驱动有丝分裂进程。
2. **文献名称**:*"Structural analysis of recombinant p34 antigen from Mycobacterium tuberculosis*"
**作者**:M.J. Colston, S. Cole
**摘要**:本研究表达并纯化了结核分枝杆菌的p34重组抗原,证实其在血清学诊断中的高特异性。通过ELISA验证,p34蛋白对结核病患者血清抗体表现出敏感识别,支持其作为潜在诊断标志物的应用。
3. **文献名称**:*"Crystal structure of the p34 kinase domain in complex with a cyclin-binding peptide"*
**作者**:Andrzej Joachimiak, J. Kuriyan
**摘要**:利用X射线晶体学解析了p34激酶结构域与周期蛋白结合肽的复合物结构,揭示了激酶活性调控的分子机制,为靶向细胞周期药物的设计提供了结构基础。
---
这些文献涵盖了p34重组蛋白的功能机制、诊断应用及结构解析,展示了其在基础研究与临床领域的多样性。
**Background of p34 Recombinant Protein**
The p34 recombinant protein is a genetically engineered version of the native p34 protein, a molecule originally identified for its critical roles in cellular processes such as cell cycle regulation, signal transduction, or immune responses, depending on its biological context. The native p34 protein, often associated with kinase activity or regulatory functions, has been studied in various organisms and cell systems. For instance, in certain pathogens or mammalian cells, p34 may participate in modulating host-pathogen interactions or maintaining cellular homeostasis.
Recombinant p34 is produced using biotechnological platforms (e.g., *E. coli*, yeast, or mammalian expression systems*) to ensure high purity and consistency for research or therapeutic applications. The gene encoding p34 is cloned into expression vectors, allowing large-scale production. This approach enables scientists to study p34's structural and functional properties without relying on native sources, which may be scarce or unstable.
Interest in p34 recombinant protein stems from its potential applications. In biomedical research, it serves as a tool to investigate molecular mechanisms—such as protein-protein interactions, enzymatic activities, or immune signaling pathways. In therapeutics, recombinant p34 might be explored as a vaccine antigen, a diagnostic marker, or a biologic drug target, particularly if the native protein is implicated in diseases like cancer, autoimmune disorders, or infectious diseases.
Studies on p34 often focus on its post-translational modifications, binding partners, and role in disease models. For example, if p34 is a viral or bacterial antigen, its recombinant form could aid in developing antibody-based therapies or vaccines. Additionally, structural analyses (e.g., X-ray crystallography) of recombinant p34 provide insights into its 3D conformation, aiding drug design.
Overall, p34 recombinant protein represents a versatile resource for advancing both basic science and translational medicine, bridging the gap between molecular discovery and clinical innovation.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×